Literature DB >> 9662944

[Endocrine orbitopathy 1998].

G Förster1, G Kahaly.   

Abstract

BACKGROUND: Ophthalmopathy is the most common extrathyroidal manifestation of Graves' disease, also called thyroid-associated ophthalmopathy. CLINICS: This autoimmune disorder is characterized by a lymphocyte infiltration of the retrobulbar space. Activated T cells react with the target organ and secrete cytokines, leading to accumulation of glycosaminoglycans, interstitial edema of the peri- and retrobulbar tissue and enlargement of the extraocular muscles. During the inflammatory stage, the increased orbital pressure results in the clinical manifestation of the eye disease. DIAGNOSIS AND TREATMENT: Thus, therapeutic immunosuppression is often used initially, and by suppressing inflammatory changes, it can result in subjective and objective improvement of the thyroid eye disease. In recent years, new pathogenetic aspects and clinical randomized trials led to modified therapy concepts.
CONCLUSION: Interdisciplinary management is recommended for rapid diagnosis and effective therapy of patients with thyroid-associated ophthalmopathy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9662944     DOI: 10.1007/bf03044681

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  72 in total

1.  Orbital tissue-derived T lymphocytes from patients with Graves' ophthalmopathy recognize autologous orbital antigens.

Authors:  E A Otto; K Ochs; C Hansen; J R Wall; G J Kahaly
Journal:  J Clin Endocrinol Metab       Date:  1996-08       Impact factor: 5.958

Review 2.  Graves' ophthalmopathy: current concepts regarding pathogenesis and management.

Authors:  H B Burch; L Wartofsky
Journal:  Endocr Rev       Date:  1993-12       Impact factor: 19.871

3.  Adhesion molecule expression in vivo on extraocular muscles (EOM) in thyroid-associated ophthalmopathy (TAO).

Authors:  A Pappa; V Calder; P Fells; S Lightman
Journal:  Clin Exp Immunol       Date:  1997-05       Impact factor: 4.330

4.  Localization and clinical significance of thyrotropin receptor mRNA expression in orbital fat and eye muscle tissues from patients with thyroid-associated ophthalmopathy.

Authors:  Y Hiromatsu; M Sato; Y Inoue; M Koga; I Miyake; J Kameo; S Tokisawa; D Yang; K Nonaka
Journal:  Thyroid       Date:  1996-12       Impact factor: 6.568

5.  High-dose intravenous steroid pulse therapy in thyroid-associated ophthalmopathy.

Authors:  T Tagami; K Tanaka; H Sugawa; H Nakamura; Y Miyoshi; T Mori; K Nakao
Journal:  Endocr J       Date:  1996-12       Impact factor: 2.349

6.  Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy.

Authors:  M F Prummel; M P Mourits; A Berghout; E P Krenning; R van der Gaag; L Koornneef; W M Wiersinga
Journal:  N Engl J Med       Date:  1989-11-16       Impact factor: 91.245

7.  Indium-111-pentetreotide scintigraphy in Graves' ophthalmopathy.

Authors:  G Kahaly; M Diaz; K Hahn; J Beyer; A Bockisch
Journal:  J Nucl Med       Date:  1995-04       Impact factor: 10.057

8.  Soluble intercellular adhesion molecule-1 (sICAM-1) in sera of patients with Graves' ophthalmopathy and thyroid diseases.

Authors:  A E Heufelder; R S Bahn
Journal:  Clin Exp Immunol       Date:  1993-05       Impact factor: 4.330

9.  Detection of TSH receptor RNA in cultured fibroblasts from patients with Graves' ophthalmopathy and pretibial dermopathy.

Authors:  A E Heufelder; C M Dutton; G Sarkar; K A Donovan; R S Bahn
Journal:  Thyroid       Date:  1993       Impact factor: 6.568

10.  Interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptor inhibit IL-1-induced glycosaminoglycan production in cultured human orbital fibroblasts from patients with Graves' ophthalmopathy.

Authors:  G H Tan; C M Dutton; R S Bahn
Journal:  J Clin Endocrinol Metab       Date:  1996-02       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.